

**IDENTIFICATION OF VIRULENCE DETERMINANTS****CROSS-REFERENCE TO RELATED APPLICATIONS**

This application claims the benefit of provisional application 60/175,433, filed January 11, 2000, which is hereby incorporated by reference in its entirety for all purposes.

**GOVERNMENT INTERESTS**

This invention was made with government support under grant number CGP-USDA 1999-02316 awarded by United States Department of Agriculture. The government has certain rights in this invention.

**BACKGROUND**

Paratuberculosis (Johne's disease) is an incurable, fatal disease of domestic and wild ruminants. *Mycobacterium paratuberculosis* (*M. paratuberculosis*) is the etiologic agent of this disease. *Mycobacterium avium* (*M. avium*) and *M. paratuberculosis* are slow-growing facultative intracellular mycobacteria able to grow in mononuclear phagocytes. DNA-DNA hybridization studies have shown that these micro-organisms belong to a single genomic species (Hurley et al., *Intl. J. Syst. Bacteriol.*, 38:143-146, 1988), and it has been proposed to reclassify *M. paratuberculosis* as a subspecies of *M. avium* (Thorel et al., *Intl. J. Syst. Bacteriol.* 40:254-260, 1990). Furthermore, all *M. paratuberculosis* strains are characterized by the presence of the insertion sequence IS900 (Green et al., *Nucleic Acids Res.*, 17:9063-9073, 1989), which is absent from most *M. avium* strains. Phenotypic differences between *M. avium* and *M. paratuberculosis*, such as mycobactin requirement, ability to grow on egg medium, growth stimulation by pyruvate, and tolerance to cycloserine correlate with variations in pathogenicity and host range (Thorel et al., *Intl. J. Syst. Bacteriol.* 40:254-260, 1990).

Johne's disease is manifested by chronic diarrhea and weight loss. After months of diarrhea and wasting, the affected animals either die or are culled. In the United States, the prevalence of *M. paratuberculosis* infection in dairy and beef cattle herds has reached 34% in certain areas (Collins et al., *J. Am. Vet. Med. Assn.* 187:323-329, 1992; Collins et al., *J. Am. Vet. Med. Assn.* 204:636-641, 1994) and results in millions of dollars in lost revenues annually. Furthermore, *M. paratuberculosis* has been tentatively linked to Crohn's disease, a

chronic granulomatous ileitis in humans. Evidence supporting the possibility that *M. paratuberculosis* is the etiologic agent of Crohn's disease includes culture of *M. paratuberculosis* from intestinal tissue, and amplification by PCR of the subspecies-specific IS900 sequence of *M. paratuberculosis* from biopsy specimens.

5 Natural infection in cattle is usually acquired in the first months of life. The age of onset of clinical Johne's disease varies, being most frequent during or after the second lactation in dairy cattle. The prolonged incubation time and the difficulty in diagnosing subclinical cases facilitate the insidious spread of the infection within a herd. Bacteriologic culture is the most definitive diagnostic method, but requires substantial time and labor (Stabel, *J. Vet. Diag. Invest.*, 9:375-380, 1997), and it is unable to detect infected animals that do not shed acid-fast bacilli. Progress has been made by combining fecal culture, PCR detection (IS900), and tests for humoral (ELISA) or cellular immunity (IFN- $\gamma$  test) (Collins, *Proceedings of the Fifth Intl. Colloq. Paratuberculosis*, Chiodini et al., eds., Intl. Assn. for Paratuberculosis, 1997, pp. 232-241.). More recently, a gene unique to *M. paratuberculosis* (*hspX*) was identified and has promise as a new diagnostic tool (Ellingson et al., *Mol. Cell Probes* 12:133-142, 1998).

10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000  
1005  
1010  
1015  
1020  
1025  
1030  
1035  
1040  
1045  
1050  
1055  
1060  
1065  
1070  
1075  
1080  
1085  
1090  
1095  
1100  
1105  
1110  
1115  
1120  
1125  
1130  
1135  
1140  
1145  
1150  
1155  
1160  
1165  
1170  
1175  
1180  
1185  
1190  
1195  
1200  
1205  
1210  
1215  
1220  
1225  
1230  
1235  
1240  
1245  
1250  
1255  
1260  
1265  
1270  
1275  
1280  
1285  
1290  
1295  
1300  
1305  
1310  
1315  
1320  
1325  
1330  
1335  
1340  
1345  
1350  
1355  
1360  
1365  
1370  
1375  
1380  
1385  
1390  
1395  
1400  
1405  
1410  
1415  
1420  
1425  
1430  
1435  
1440  
1445  
1450  
1455  
1460  
1465  
1470  
1475  
1480  
1485  
1490  
1495  
1500  
1505  
1510  
1515  
1520  
1525  
1530  
1535  
1540  
1545  
1550  
1555  
1560  
1565  
1570  
1575  
1580  
1585  
1590  
1595  
1600  
1605  
1610  
1615  
1620  
1625  
1630  
1635  
1640  
1645  
1650  
1655  
1660  
1665  
1670  
1675  
1680  
1685  
1690  
1695  
1700  
1705  
1710  
1715  
1720  
1725  
1730  
1735  
1740  
1745  
1750  
1755  
1760  
1765  
1770  
1775  
1780  
1785  
1790  
1795  
1800  
1805  
1810  
1815  
1820  
1825  
1830  
1835  
1840  
1845  
1850  
1855  
1860  
1865  
1870  
1875  
1880  
1885  
1890  
1895  
1900  
1905  
1910  
1915  
1920  
1925  
1930  
1935  
1940  
1945  
1950  
1955  
1960  
1965  
1970  
1975  
1980  
1985  
1990  
1995  
2000  
2005  
2010  
2015  
2020  
2025  
2030  
2035  
2040  
2045  
2050  
2055  
2060  
2065  
2070  
2075  
2080  
2085  
2090  
2095  
2100  
2105  
2110  
2115  
2120  
2125  
2130  
2135  
2140  
2145  
2150  
2155  
2160  
2165  
2170  
2175  
2180  
2185  
2190  
2195  
2200  
2205  
2210  
2215  
2220  
2225  
2230  
2235  
2240  
2245  
2250  
2255  
2260  
2265  
2270  
2275  
2280  
2285  
2290  
2295  
2300  
2305  
2310  
2315  
2320  
2325  
2330  
2335  
2340  
2345  
2350  
2355  
2360  
2365  
2370  
2375  
2380  
2385  
2390  
2395  
2400  
2405  
2410  
2415  
2420  
2425  
2430  
2435  
2440  
2445  
2450  
2455  
2460  
2465  
2470  
2475  
2480  
2485  
2490  
2495  
2500  
2505  
2510  
2515  
2520  
2525  
2530  
2535  
2540  
2545  
2550  
2555  
2560  
2565  
2570  
2575  
2580  
2585  
2590  
2595  
2600  
2605  
2610  
2615  
2620  
2625  
2630  
2635  
2640  
2645  
2650  
2655  
2660  
2665  
2670  
2675  
2680  
2685  
2690  
2695  
2700  
2705  
2710  
2715  
2720  
2725  
2730  
2735  
2740  
2745  
2750  
2755  
2760  
2765  
2770  
2775  
2780  
2785  
2790  
2795  
2800  
2805  
2810  
2815  
2820  
2825  
2830  
2835  
2840  
2845  
2850  
2855  
2860  
2865  
2870  
2875  
2880  
2885  
2890  
2895  
2900  
2905  
2910  
2915  
2920  
2925  
2930  
2935  
2940  
2945  
2950  
2955  
2960  
2965  
2970  
2975  
2980  
2985  
2990  
2995  
3000  
3005  
3010  
3015  
3020  
3025  
3030  
3035  
3040  
3045  
3050  
3055  
3060  
3065  
3070  
3075  
3080  
3085  
3090  
3095  
3100  
3105  
3110  
3115  
3120  
3125  
3130  
3135  
3140  
3145  
3150  
3155  
3160  
3165  
3170  
3175  
3180  
3185  
3190  
3195  
3200  
3205  
3210  
3215  
3220  
3225  
3230  
3235  
3240  
3245  
3250  
3255  
3260  
3265  
3270  
3275  
3280  
3285  
3290  
3295  
3300  
3305  
3310  
3315  
3320  
3325  
3330  
3335  
3340  
3345  
3350  
3355  
3360  
3365  
3370  
3375  
3380  
3385  
3390  
3395  
3400  
3405  
3410  
3415  
3420  
3425  
3430  
3435  
3440  
3445  
3450  
3455  
3460  
3465  
3470  
3475  
3480  
3485  
3490  
3495  
3500  
3505  
3510  
3515  
3520  
3525  
3530  
3535  
3540  
3545  
3550  
3555  
3560  
3565  
3570  
3575  
3580  
3585  
3590  
3595  
3600  
3605  
3610  
3615  
3620  
3625  
3630  
3635  
3640  
3645  
3650  
3655  
3660  
3665  
3670  
3675  
3680  
3685  
3690  
3695  
3700  
3705  
3710  
3715  
3720  
3725  
3730  
3735  
3740  
3745  
3750  
3755  
3760  
3765  
3770  
3775  
3780  
3785  
3790  
3795  
3800  
3805  
3810  
3815  
3820  
3825  
3830  
3835  
3840  
3845  
3850  
3855  
3860  
3865  
3870  
3875  
3880  
3885  
3890  
3895  
3900  
3905  
3910  
3915  
3920  
3925  
3930  
3935  
3940  
3945  
3950  
3955  
3960  
3965  
3970  
3975  
3980  
3985  
3990  
3995  
4000  
4005  
4010  
4015  
4020  
4025  
4030  
4035  
4040  
4045  
4050  
4055  
4060  
4065  
4070  
4075  
4080  
4085  
4090  
4095  
4100  
4105  
4110  
4115  
4120  
4125  
4130  
4135  
4140  
4145  
4150  
4155  
4160  
4165  
4170  
4175  
4180  
4185  
4190  
4195  
4200  
4205  
4210  
4215  
4220  
4225  
4230  
4235  
4240  
4245  
4250  
4255  
4260  
4265  
4270  
4275  
4280  
4285  
4290  
4295  
4300  
4305  
4310  
4315  
4320  
4325  
4330  
4335  
4340  
4345  
4350  
4355  
4360  
4365  
4370  
4375  
4380  
4385  
4390  
4395  
4400  
4405  
4410  
4415  
4420  
4425  
4430  
4435  
4440  
4445  
4450  
4455  
4460  
4465  
4470  
4475  
4480  
4485  
4490  
4495  
4500  
4505  
4510  
4515  
4520  
4525  
4530  
4535  
4540  
4545  
4550  
4555  
4560  
4565  
4570  
4575  
4580  
4585  
4590  
4595  
4600  
4605  
4610  
4615  
4620  
4625  
4630  
4635  
4640  
4645  
4650  
4655  
4660  
4665  
4670  
4675  
4680  
4685  
4690  
4695  
4700  
4705  
4710  
4715  
4720  
4725  
4730  
4735  
4740  
4745  
4750  
4755  
4760  
4765  
4770  
4775  
4780  
4785  
4790  
4795  
4800  
4805  
4810  
4815  
4820  
4825  
4830  
4835  
4840  
4845  
4850  
4855  
4860  
4865  
4870  
4875  
4880  
4885  
4890  
4895  
4900  
4905  
4910  
4915  
4920  
4925  
4930  
4935  
4940  
4945  
4950  
4955  
4960  
4965  
4970  
4975  
4980  
4985  
4990  
4995  
5000  
5005  
5010  
5015  
5020  
5025  
5030  
5035  
5040  
5045  
5050  
5055  
5060  
5065  
5070  
5075  
5080  
5085  
5090  
5095  
5100  
5105  
5110  
5115  
5120  
5125  
5130  
5135  
5140  
5145  
5150  
5155  
5160  
5165  
5170  
5175  
5180  
5185  
5190  
5195  
5200  
5205  
5210  
5215  
5220  
5225  
5230  
5235  
5240  
5245  
5250  
5255  
5260  
5265  
5270  
5275  
5280  
5285  
5290  
5295  
5300  
5305  
5310  
5315  
5320  
5325  
5330  
5335  
5340  
5345  
5350  
5355  
5360  
5365  
5370  
5375  
5380  
5385  
5390  
5395  
5400  
5405  
5410  
5415  
5420  
5425  
5430  
5435  
5440  
5445  
5450  
5455  
5460  
5465  
5470  
5475  
5480  
5485  
5490  
5495  
5500  
5505  
5510  
5515  
5520  
5525  
5530  
5535  
5540  
5545  
5550  
5555  
5560  
5565  
5570  
5575  
5580  
5585  
5590  
5595  
5600  
5605  
5610  
5615  
5620  
5625  
5630  
5635  
5640  
5645  
5650  
5655  
5660  
5665  
5670  
5675  
5680  
5685  
5690  
5695  
5700  
5705  
5710  
5715  
5720  
5725  
5730  
5735  
5740  
5745  
5750  
5755  
5760  
5765  
5770  
5775  
5780  
5785  
5790  
5795  
5800  
5805  
5810  
5815  
5820  
5825  
5830  
5835  
5840  
5845  
5850  
5855  
5860  
5865  
5870  
5875  
5880  
5885  
5890  
5895  
5900  
5905  
5910  
5915  
5920  
5925  
5930  
5935  
5940  
5945  
5950  
5955  
5960  
5965  
5970  
5975  
5980  
5985  
5990  
5995  
6000  
6005  
6010  
6015  
6020  
6025  
6030  
6035  
6040  
6045  
6050  
6055  
6060  
6065  
6070  
6075  
6080  
6085  
6090  
6095  
6100  
6105  
6110  
6115  
6120  
6125  
6130  
6135  
6140  
6145  
6150  
6155  
6160  
6165  
6170  
6175  
6180  
6185  
6190  
6195  
6200  
6205  
6210  
6215  
6220  
6225  
6230  
6235  
6240  
6245  
6250  
6255  
6260  
6265  
6270  
6275  
6280  
6285  
6290  
6295  
6300  
6305  
6310  
6315  
6320  
6325  
6330  
6335  
6340  
6345  
6350  
6355  
6360  
6365  
6370  
6375  
6380  
6385  
6390  
6395  
6400  
6405  
6410  
6415  
6420  
6425  
6430  
6435  
6440  
6445  
6450  
6455  
6460  
6465  
6470  
6475  
6480  
6485  
6490  
6495  
6500  
6505  
6510  
6515  
6520  
6525  
6530  
6535  
6540  
6545  
6550  
6555  
6560  
6565  
6570  
6575  
6580  
6585  
6590  
6595  
6600  
6605  
6610  
6615  
6620  
6625  
6630  
6635  
6640  
6645  
6650  
6655  
6660  
6665  
6670  
6675  
6680  
6685  
6690  
6695  
6700  
6705  
6710  
6715  
6720  
6725  
6730  
6735  
6740  
6745  
6750  
6755  
6760  
6765  
6770  
6775  
6780  
6785  
6790  
6795  
6800  
6805  
6810  
6815  
6820  
6825  
6830  
6835  
6840  
6845  
6850  
6855  
6860  
6865  
6870  
6875  
6880  
6885  
6890  
6895  
6900  
6905  
6910  
6915  
6920  
6925  
6930  
6935  
6940  
6945  
6950  
6955  
6960  
6965  
6970  
6975  
6980  
6985  
6990  
6995  
7000  
7005  
7010  
7015  
7020  
7025  
7030  
7035  
7040  
7045  
7050  
7055  
7060  
7065  
7070  
7075  
7080  
7085  
7090  
7095  
7100  
7105  
7110  
7115  
7120  
7125  
7130  
7135  
7140  
7145  
7150  
7155  
7160  
7165  
7170  
7175  
7180  
7185  
7190  
7195  
7200  
7205  
7210  
7215  
7220  
7225  
7230  
7235  
7240  
7245  
7250  
7255  
7260  
7265  
7270  
7275  
7280  
7285  
7290  
7295  
7300  
7305  
7310  
7315  
7320  
7325  
7330  
7335  
7340  
7345  
7350  
7355  
7360  
7365  
7370  
7375  
7380  
7385  
7390  
7395  
7400  
7405  
7410  
7415  
7420  
7425  
7430  
7435  
7440  
7445  
7450  
7455  
7460  
7465  
7470  
7475  
7480  
7485  
7490  
7495  
7500  
7505  
7510  
7515  
7520  
7525  
7530  
7535  
7540  
7545  
7550  
7555  
7560  
7565  
7570  
7575  
7580  
7585  
7590  
7595  
7600  
7605  
7610  
7615  
7620  
7625  
7630  
7635  
7640  
7645  
7650  
7655  
7660  
7665  
7670  
7675  
7680  
7685  
7690  
7695  
7700  
7705  
7710  
7715  
7720  
7725  
7730  
7735  
7740  
7745  
7750  
7755  
7760  
7765  
7770  
7775  
7780  
7785  
7790  
7795  
7800  
7805  
7810  
7815  
7820  
7825  
7830  
7835  
7840  
7845  
7850  
7855  
7860  
7865  
7870  
7875  
7880  
7885  
7890  
7895  
7900  
7905  
7910  
7915  
7920  
7925  
7930  
7935  
7940  
7945  
7950  
7955  
7960  
7965  
7970  
7975  
7980  
7985  
7990  
7995  
8000  
8005  
8010  
8015  
8020  
8025  
8030  
8035  
8040  
8045  
8050  
8055  
8060  
8065  
8070  
8075  
8080  
8085  
8090  
8095  
8100  
8105  
8110  
8115  
8120  
8125  
8130  
8135  
8140  
8145  
8150  
8155  
8160  
8165  
8170  
8175  
8180  
8185  
8190  
8195  
8200  
8205  
8210  
8215  
8220  
8225  
8230  
8235  
8240  
8245  
8250  
8255  
8260  
8265  
8270  
8275  
8280  
8285  
8290  
8295  
8300  
8305  
8310  
8315  
8320  
8325  
8330  
8335  
8340  
8345  
8350  
8355  
8360  
8365  
8370  
8375  
8380  
8385  
8390  
8395  
8400  
8405  
8410  
8415  
8420  
8425  
8430  
8435  
8440  
8445  
8450  
8455  
8460  
8465  
8470  
8475  
8480  
8485  
8490  
8495  
8500  
8505  
8510  
8515  
8520  
8525  
8530  
8535  
8540  
8545  
8550  
8555  
8560  
8565  
8570  
8575  
8580  
8585  
8590  
8595  
8600  
8605  
8610  
8615  
8620  
8625  
8630  
8635  
8640  
8645  
8650  
8655  
8660  
8665  
8670  
8675  
8680  
8685  
8690  
8695  
8700  
8705  
8710  
8715  
8720  
8725  
8730  
8735  
8740  
8745  
8750  
8755  
8760  
8765  
8770  
8775  
8780  
8785  
8790  
8795  
8800  
8805  
8810  
8815  
8820  
8825  
8830  
8835  
8840  
8845  
8850  
8855  
8860  
8865  
8870  
8875  
8880  
8885  
8890  
8895  
8900  
8905  
8910  
8915  
8920  
8925  
8930  
8935  
8940  
8945  
8950  
8955  
8960  
8965  
8970  
8975  
8980  
8985  
8990  
8995  
9000  
9005  
9010  
9015  
9020  
9025  
9030  
9035  
9040  
9045  
9050  
9055  
9060  
9065  
9070  
9075  
9080  
9085  
9090  
9095  
9100  
9105  
9110  
9115  
9120  
9125  
9130  
9135  
9140  
9145  
9150  
9155  
9160  
9165  
9170  
9175  
9180  
9185  
9190  
9195  
9200  
9205  
9210  
9215  
9220  
9225  
9230  
9235  
9240  
9245  
9250  
9255  
9260  
9265  
9270  
9275  
9280  
9285  
9290  
9295  
9300  
9305  
9310  
9315  
9320  
9325  
9330  
9335  
9340  
9345  
9350  
9355  
9360  
9365  
9370  
9375  
9380  
9385  
9390  
9395  
9400  
9405  
9410  
9415  
9420  
9425  
9430  
9435  
9440  
9445  
9450  
9455  
9460  
9465  
9470  
9475  
9480  
9485  
9490  
9495  
9500  
9505  
9510  
9515  
9520  
9525  
9530  
9535  
9540  
9545  
9550  
9555  
9560  
9565  
9570  
9575  
9580  
9585  
9590  
9595  
9600  
9605  
9610  
9615  
9620  
9625  
9630  
9635  
9640  
9645  
9650  
9655  
9660  
9665  
9670  
9675  
9680  
9685  
9690  
9695  
9700  
9705  
9710  
9715  
9720  
9725  
9730  
9735  
9740  
9745  
9750  
9755  
9760  
9765  
9770  
9775  
9780  
9785  
9790  
9795  
9800  
9805  
9810  
9815  
9820  
9825  
9830  
9835  
9840  
9845  
9850  
9855  
9860  
9865  
9870  
9875  
9880  
9885  
9890  
9895  
9900  
9905  
9910  
9915  
9920  
9925  
9930  
9935  
9940  
9945  
9950  
9955  
9960  
9965  
9970  
9975  
9980  
9985  
9990  
9995  
10000  
10005  
10010  
10015  
10020  
10025  
10030

electrophoretic profiles of *M. paratuberculosis* and *M. avium* cells grown in Middlebrook 7H9 medium followed by Western blot analysis, using antiserum from clinically infected cows, revealed a 42 kDa protein which may be specific for *M. paratuberculosis* (White et al., *Am. J. Vet. Res.*, 55:1399-1405, 1994). Using the same methodology, AHPC gene products were identified that may be antigenic (Hsieh et al., *Proceed. Fifth Intl. Colloq. Paratuberculosis*, Chiodini et al., eds., 1997, pp. 82-87).

*M. paratuberculosis* antigens that have been cloned include the heat shock proteins HSP65 and HSP70, the transposase form IS900, a putative serine protease, bacterioferritin, the 34 kDa antigen bearing major B cell epitopes (reviewed by Stevenson and Sharp, *Vet. J.* 153:269-286, 1997), and more recently, the 35 kDa antigen (El Zaatari et al., *J. Clin. Microbiol.* 35:1794-1799, 1997) and the Hed protein from IS900 (Doran et al., *Microbiol.* 143:547-552, 1997). In addition, a novel extracellular ferric reductase enzyme activity with a potential role in the evasion of intracellular defense mechanisms has been identified (Homuth et al., *Infect. Immun.*, 66:710-716, 1998). Secreted proteins of *M. paratuberculosis* have received attention as potential immune targets early in infection. Some of these proteins are present as glyconjugates and different epitopes in the glycosylated and non-glycosylated moieties seem to be recognized in cattle and sheep (Mutharia et al, *Infect. Immun.* 65:387-394, 1997).

Diagnosis and control of paratuberculosis presents a significant challenge. Although vaccination does reduce clinical signs of Johne's disease, it does not prevent losses in milk production (van Schaik et al., *Vet. Rec.*, 139:624-627, 1996). Improved vaccines and diagnostic tools are urgently needed. Likewise faster, specific, and more accurate and sensitive diagnostics need to be developed, especially to detect animals in the early stages of the disease. These tools preferably should also be able to discriminate between vaccinated and infected animals.

Identification of *M. paratuberculosis* virulence determinants is a critical step in developing suitable methods of diagnosis and control, and requires a systematic method by which virulence determinants can be found. U.S. Patent No. 5,783,386 to Jacobs et al. describes a method for identifying virulence determinants of mycobacterial species involving the preparation of a genomic DNA library and constructing shuttle vectors containing inserts from the library constructed. These vectors are then used to transform avirulent organisms to form recombinants. Virulence determinants are identified by inoculating animals with the

transformed recombinant organisms to select virulent recombinants and then identifying the DNA sequences that confer virulence. Cavaignac, et al. (*Arch. Microbiol.* 173:229-231, 2000) studied virulence mechanisms in *M. paratuberculosis* by the introduction of random mutants using transposon mutagenesis. Two thousand mutants were screened on the basis of auxotrophy and altered cell wall. Pelicic et al. (U.S. Patent No. 6,096,549) disclose a method for inserting a transposon into a mycobacterium strain using a vector containing the *sacB* gene. Use of this vector to identify virulence determinants is also disclosed. The present disclosure teaches an alternative method utilizing transposon mediated mutation and positive selection of mutants by antimicrobial agents that kill growing mycobacteria..

### SUMMARY

Among the several aspects of the invention is provided a method for identifying virulence determinants of a bacteria comprising introducing at least one mutation into the genome of a bacteria; culturing the mutated bacteria in the presence of an antimicrobial agent that kills growing but not non-growing bacteria; selecting surviving bacteria; testing the selected surviving bacteria for virulence; selecting the non virulent bacteria; sequencing genetic material from the selected non virulent bacteria; determining the site of mutation; and comparing the sequence at the mutated site to the corresponding wild type sequence.

Another aspect provides a composition for immunizing an animal against bacterial infection comprising a pharmaceutically acceptable carrier, diluent or excipient; and at least one non-virulent strain of bacteria produced by the process comprising introducing at least one mutation into the genome of a bacteria; culturing the mutated bacteria in the presence of an antimicrobial agent that kills growing but not non-growing bacteria; selecting surviving bacteria; testing the selected surviving bacteria for virulence; and selecting the non-virulent strains.

Still another aspect provides a composition for immunizing an animal against a bacteria comprising a pharmaceutically acceptable carrier diluent or excipient; and at least one bacterial virulence determinant, the determinant identified by a process comprising; introducing at least one mutation into the genome of a bacteria; culturing the mutated bacteria in the presence of an antimicrobial agent that kills growing but not non-growing bacteria; selecting surviving bacteria; testing the selected surviving bacteria for virulence; selecting the non-virulent strains;

sequencing genetic material from the selected non-virulent bacteria to determine the site of the mutation; and identifying the virulence determinant based on the site of the mutation.

Yet another aspect provides a method for inducing an immune response in an animal against a bacteria comprising administering to an animal an immune response inducing amount of any of the previously described compositions.

Another aspect provides a method for diagnosing infection by *Mycobacterium paratuberculosis* comprising obtaining a sample from an animal and determining the presence or absence in the sample of a bacterial virulence determinant, said determinant identified by the methods described above.

### BRIEF DESCRIPTION OF THE DRAWINGS

These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, appended claims and accompanying figures where:

Figure 1 shows Southern blot analysis of *M. paratuberculosis* K-10 true transposon mutants.

Figure 2 shows the location of the BETH-R and BETH-F primers in the Tn5367 transposon and partial results of sequencing. Also shown is the alignment of nucleotide sequence obtained from mutant GPM207 (SEQ ID NO: 5) using BETH-F and the *xerC* gene (GenBank No. Z97369) (SEQ ID NO: 6).

Figure 3 shows the effects of co-culture with either Bay y 3118 or D-cycloserine on growing and non-growing *M. paratuberculosis* strain K-10 in complete Middlebrook 7H9 medium.

### ABBREVIATIONS AND DEFINITIONS

cfu = colony forming unit

pfu = plaque forming unit

MIC = minimal inhibitory concentration

"Albumin dextrose complex" means 2 g glucose, 5 g bovine serum albumin fraction V and 0.85 g NaCl in 100 mL deionized water.

As used herein "polynucleotide" and "oligonucleotide" are used interchangeably and refer to a polymeric (2 or more monomers) form of nucleotides of any length, either

ribonucleotides or deoxyribonucleotides. Although nucleotides are usually joined by phosphodiester linkages, the term also includes polymeric nucleotides containing neutral amide backbone linkages composed of aminoethyl glycine units. This term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA and RNA. It also includes known types of modifications, for example, labels, methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), those containing pendant moieties, such as, for example, proteins (including for e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide. Polynucleotides include both sense and antisense strands.

As used herein "polypeptide", "protein" and "peptide" are used interchangeably and refer to a polymer of two or more amino acids. Included within the definition are polypeptides containing one or more analogs of an amino acid, including, for example, unnatural amino acids, polypeptides with substituted linkages, as well as modifications known in the art, both naturally occurring and non-naturally occurring.

As used herein, the term "animal" includes human beings.

As used herein, the term "patient" includes humans and animals.

## DETAILED DESCRIPTION

The following detailed description is provided to aid those skilled in the art in practicing the present invention. Even so, this detailed description should not be construed to unduly limit the present invention as modifications and variations in the embodiments discussed herein can be made by those of ordinary skill in the art without departing from the spirit or scope of the present inventive discovery.

All publications, patents, patent applications, databases and other references cited in this application are herein incorporated by reference in their entirety as if each individual publication, patent, patent application, database or other reference were specifically and individually indicated to be incorporated by reference.

The present invention relates to the identification of virulence determinants in bacteria particularly in members of the genus *Mycobacteria*. The genus *Mycobacteria* includes the species *M. phlei*, *M. smegmatis*, *M. africanum*, *M. fortuitum*, *M. marinum*, *M. ulcerans*, *M. tuberculosis*, *M. bovis*, *M. microti*, *M. avium*, *M. paratuberculosis*, *M. leprae*, *M. lepraemurium*, *M. intracellulare*, *M. scrofulaceum*, *M. xenopi*, *M. genavense*, *M. kansasii*, *M. simiae*, *M. szulgai*, *M. Haemophilum*, *M. asiaticum*, *M. amlmoense*, and *M. shimoidei*. In one embodiment, the mycobacteria are slow growing mycobacteria. Any virulent strain of a species of mycobacterium that is slow growing and capable of being maintained *in vitro* can be used in the practice of the present invention. Examples of slow growing mycobacteria include *M. tuberculosis*, *M. bovis*, *M. africanum*, *M. marinum*, *M. avium*, and *M. paratuberculosis*. In one embodiment, strains of *M. paratuberculosis* are used and in particular the virulent strain K-10 of *M. paratuberculosis*.

Once a particular strain or strains has been chosen, mutations are introduced into the genome of the selected bacteria. Numerous means for inserting mutations into the genome of bacteria are known in the art and can be found in standard references such as Sambrook et al. *Molecular Cloning*, 2nd ed., Cold Spring Harbor Press, 1989 and Ausubel et al., *Short Protocols in Molecular Biology*, 3rd ed., Wiley, 1995. A discussion of methods of mutagenesis directed particularly to mycobacteria can be found in Jacobs et al., *Methods in Enzymology*, 204:537-555, 1991 and Pelicic et al., *Molec. Microbiol.*, 28:413-420, 1998. Mutations introduced can be site directed to a particular gene or sequence of interest, or the location of the mutations can be random. If random mutation is used, it is preferred that the mutations be approximately evenly distributed throughout the genome. Two particularly useful forms of mutagenesis are allelic exchange mutagenesis and transposon mutagenesis although other forms of mutagenesis such as chemical and enzymatic (e.g. restriction enzyme mediated integration) mutagenesis can be used.

In allelic exchange mutagenesis, the gene or sequence of interest is disrupted using homologous recombination such that the functional allele is replaced with an inactivated copy. Following introduction of the inactivated copy, the virulence of the transformed bacteria can be compared to the parental strain. The efficiency of allelic exchange mutation is improved through the use of counter selection strategies which eliminate transformants retaining the delivery vector. Successful allelic exchange mutations have been achieved in mycobacteria (U.S. Patent No. 6,096,549; Balasubramanian et al., *J. Bacterol.* 178:273-279,

1996; McFadden, *Molec. Microbiol.*, 21:205-211, 1996; Pelicic et al., *Proc. Natl. Acad. Sci USA*, 94:10955-10960, 1997).

In one embodiment, the introduction of mutations is by transposon mutagenesis. Transposon mutagenesis occurs by the insertion of a mobile element called a transposon into the gene or sequence of interest, thus disrupting its function. An advantage of transposon mutagenesis is that no previous assumptions need to be made regarding the identity of the gene or sequence to be disrupted. In general, a transposon contains an inverted repeat sequence at the 5' and 3' ends and a gene or genes encoding transposase enzyme(s) between the inverted repeats. In transposon mutagenesis, the transposon is removed from a vector and inserted or transposed into the chromosome of a bacteria to be mutated. As used herein, the term "transposon" is a general term and encompasses both non-mutated and mutated transposons. Thus, the term includes transposons in which a portion of the nucleotide sequence has been deleted and /or replaced, and/or wherein the transposon contains additional DNA sequences. Transposon mutagenesis has been successfully used in mycobacteria (Martin et al., *Nature*, 345:739-743, 1990; Guilhot et al., *J. Bacteriol.* 176:535-539, 1994; Pelicic et al., *Proc. Natl. Acad. Sci USA*, 94:10955-10960, 1997; Bardarov et al., *Proc. Natl. Acad. Sci. USA*, 94:10961-10966, 1997). In one preferred embodiment, transposon mutagenesis is accomplished by use of the transposable element Tn5367, a single-unit transposon which carries a kanamycin-resistance marker and the *M. smegmatis* insertion sequence IS 1096 (Cirillo et al., *J. Bacterol.* 173:7772-7780, 1991; McAdam et al., *Infect. Immunol.*, 1004-1012, 1995).

Introduction of vectors useful in the practice of the present invention can be accomplished by any suitable method known in the art. Various methods are known for the introduction of DNA into bacterial cells and include, for example, calcium phosphate transfection, DEAE-dextran mediated transfection, Polybrene, protoplast fusion, liposomes, phage infection, conjugation, and electroporation. Commonly, introduction of vectors for allelic exchange or transposon mutagenesis in mycobacteria is by either electroporation or phage infection. In one preferred embodiment, introduction of the DNA is by phage infection and in particular by the use of the TM4 thermosensitive transposon delivery shuttle plasmid pHAE94 (Bardarov et al. *Proc. Natl. Acad. Sci. USA*, 94:10961-10966, 1997).

In general, a shuttle plasmid comprises a bacteriophage DNA into which a plasmid sequence has been inserted into a nonessential region. In one embodiment, the bacteriophage



is from a mycobacteriophage and the plasmid sequence is a cosmid sequence, preferably an *E. coli* cosmid sequence. Shuttle phasmids can, therefore, replicate in bacteria as a plasmid/cosmid or as a phage. The inserted plasmid/cosmid DNA is preferably flanked by restriction sites not found in the bacteriophage DNA, so that the inserted DNA can be easily excised. In one embodiment, a cosmid containing a transposon is obtained and inserted into the bacteriophage backbone using standard methods of cosmid cloning (Sambrook et al., *Molecular Cloning*, 2nd ed., Cold Spring Harbor Press, 1989).

The sequence containing the transposon can, and usually does, also contain a selection marker sequence. Typically, this sequence encodes a protein necessary for the survival or growth of the host cell transformed with the shuttle plasmid. Examples of suitable markers for prokaryotic cells include tetracycline, kanamycin, and ampicillin resistance.

In one embodiment, the shuttle phasmid is a temperature sensitive phasmid. Temperature sensitive shuttle phasmids are those which replicate and form plaques at a permissive temperature, but do not undergo a lytic cycle and so do not form plaques at a non-permissive temperature.

Once the temperature sensitive shuttle phasmid has been produced it can be introduced into a bacterial host which will allow growth of the shuttle phasmid as a lytic bacteriophage at a permissive temperature. Introduction of the shuttle phasmid into the host cell can be by any method suitable for the introduction of DNA into a bacterial host including those discussed above. Introduction of the shuttle phasmid and culture at a permissive temperature results in the production of large numbers of bacteriophage particles. The bacteriophages are isolated using standard techniques and then used to infect susceptible bacteria at a non permissive temperature. At the non-permissive temperature, rather than causing lysis of the infected bacteria, the shuttle phasmid gives rise to bacterial transductants which can then be selected on the basis of a selection marker, if present.

In one preferred embodiment, introduction of the DNA is by the use of the TM4 thermosensitive transposon delivery shuttle phasmid pAE94 (Bardarov et al. *Proc. Natl. Acad. Sci. USA*, 94:10961-10966, 1997). This shuttle phasmid contains the transposon Tn5367 which is a derivative of the insertion sequence IS1096 from *M. smegmatis* and carries the *aph* gene conferring kanamycin resistance. In this embodiment, pAE94 is propagated in *M. smegmatis* at a permissive temperature and the resulting mycobacteriophage used to infect

susceptible mycobacteria at a non-permissive temperature. Mycobacteria undergoing transformation are then selected by kanamycin resistance.

Once one or more mutations have been introduced into the genome, a selection method is employed in order to select those bacteria which the mutation has disrupted a gene or nucleic acid sequence potentially involved in virulence. Various methods can be employed to determine virulence. For example, suitable host animals can be inoculated with the mutated bacteria and monitored for development of disease symptoms and/or replication of the organisms injected. Alternatively, selection can be based on the use of a chemical, and in particular, an antimicrobial, the effect of which is associated with a trait related to virulence. Since bacterial growth is a necessary part of virulence, in one embodiment the selection is based on the ability of an antimicrobial to kill growing mycobacteria while having a reduced or no effect on non-growing bacteria. Thus, antimicrobials that interfere with processes involved in bacterial growth and in particular DNA replication are preferred. Although not necessary to practice the present invention, it is preferred that the antimicrobial agent used be able to enter eukaryotic cells, thus allowing screening of transformed bacteria in intracellular culture systems, e.g. macrophage culture. In one embodiment, the antimicrobial is a quinolone. In another embodiment, the antimicrobial is a fluoroquinolone. In yet another embodiment, the antimicrobial is Bay y 3118. Bay y 3118 has been reported to kill growing but not non-growing *Mycobacterium avium* within human macrophages (Bermudez et al., *FEMS Microbiol. Lett.* 1787:19-26, 1999). In still another embodiment, the antimicrobial is D-cycloserine (Cáceres et al., *J. Bacteriol.* 179:5046-5055, 1997).

The exact amount of the antimicrobial used will vary with the particular substance and organism in question. In general, the concentration of the antimicrobial should exceed the approximate minimal inhibitory concentration (MIC) for the particular organism being studied. Determination of MIC is routine in the art and can be accomplished by the skilled technician without undue experimentation. In one embodiment, in which *M. paratuberculosis* strain K-10 and Bay y 3118 are used, the MIC is approximately 0.015 µg/mL. In another embodiment, the concentration of Bay y 3118 is 5X the MIC. In still another embodiment in which *M. paratuberculosis* strain K-10 and D-cycloserine are used the MIC is approximately 25 µg/mL. In yet another embodiment, the concentration of D-cycloserine is 5X the MIC.

In general, screening is accomplished by culturing the mutated bacteria in the presence of the antimicrobial agent. As will be apparent to those skilled in the art, the exact culture conditions will vary with the organism being studied. When *M. paratuberculosis* is used, either broth or macrophage culture can be used. Methods for the culture of mycobacteria are well known in the art and can be found, for example, in Jacobs et al., *Methods in Enzymology*, 204:537-555, 1991; Foley-Thomas et al., *Microbiology* 141:1173-1181, 1995; and Williams et al., *J. Clin. Microbiol.* 37:304-309, 1999. In one embodiment, mycobacteria are grown in Middlebrook 7H9 broth. As is known in the art and described in the references cited above, Middlebrook 7H9 broth is supplemented depending on the particular species of mycobacteria cultured. Alternatively, an intracellular culture system such as a macrophage or amoeba (Cirillo et al., *Infect. Immunol.* 65:3759-3767, 1997) culture system can be used. Mycobacteria naturally infect macrophages as part of the disease process. Thus, mycobacteria can be cultured in macrophages. In this system, mycobacteria, preferably in a single cell suspension, are added to a culture of macrophages from a suitable species. The macrophages used can be recently collected from blood using known, standard methods or can be from a macrophage cell line. The mycobacteria are allowed to infect the macrophages. The infected macrophages are then maintained under suitable culture conditions so that the mycobacteria survive and grow within the macrophages.

The antimicrobial selection agent is added to the culture system at a concentration that exceeds the MIC and the culture continued for a period of time sufficient to kill the multiplying bacteria. It will be apparent to those skilled in the art that the exact amount of time required will vary with such well known factors as the amount and type of selection agent used, the culture system, and the species of mycobacteria. In general, the selection conditions can be optimized by culturing bacteria for various times and at various concentrations of antimicrobials to determine the combination of times and concentrations which effectively kill growing, but not non-growing bacteria. Such optimization can readily be achieved by the skilled technician without undue experimentation. After the selection period, the surviving bacteria are collected, individual bacteria isolated, by for example clonal streaking, and the clones expanded using standard culture methods. If desired following expansion, the selected bacteria can be further characterized by genetic, biochemical, and animal testing.

Characterization can include determination of whether the transposon has been incorporated into the genome. This can be accomplished using well known techniques such as Southern blotting, dot or slot blots, and *in situ* hybridization to bacterial chromosomes, using a polynucleotide probe complimentary to the transposon used. Information regarding the location of the transposition and the gene or sequence disrupted can be obtained by sequencing. In general, this can be accomplished by obtaining purified genomic DNA from transfected bacteria and cutting the DNA with restriction enzymes that do not cut within the transposon. The restriction fragments obtained can be cloned into a cloning vector using standard techniques and amplified for sequencing. Any known method of sequencing can be used. In one embodiment, sequencing is accomplished by cycle sequencing outward from the transposon. Once the sequence information has been obtained, the nucleic acid sequences or deduced amino acid sequences can be compared to sequences in publically available databases such as those maintained by the National Center for Biotechnology Information at <http://www.ncbi.nlm.nih.gov/>, the European Bioinformatics Institute at <http://www.ebi.ac.uk/>, The Institute for Genomic Research at <http://www.tigr.org>, The Sanger Centre at <http://www.sanger.ac.uk/Projects/>, The Computational Biology Center of the University of Minnesota Microbial Genome Project at <http://cbc.umn.edu/>, and the Institute Pasteur at <http://genolist.pasteur.fr/>. Based on sequence homology, the identity of the gene or sequence disrupted by the insertion can be determined and thus the virulence determinant identified.

Alternatively or additionally, information can be obtained by biochemical studies, especially by auxotrophic analysis. Auxotrophic mutants are mutants that require a nutrient or substance not required by the parent organism from which the mutant was derived. Determination of auxotrophic mutants can be made by comparing growth on complete and incomplete growth medium. For those mutants showing no or reduced growth on incomplete medium, the missing nutrients can be individually added back until growth comparable to that seen with complete medium is obtained. Methods for selecting auxotrophic mutants are well known in the art and can be accomplished by the skilled technician without undue experimentation.

Whether the selected mutants lack virulence can be tested by inoculating susceptible animals with the selected organism and determining if the organism results in clinical symptoms or if the organism multiplies and spreads beyond the site of inoculation. The

animal inoculated can be the natural host for the organism or it can be a animal model. In one embodiment, the mouse model and in particular the beige mouse (Whipple et al., *Proc. 3rd Intl. Colloq Paratuberculosis*, Intl. Assn. Paratuberculosis, pp. 551-552) is used for virulence testing. In general, the animal is inoculated with a quantity of the organism sufficient to result in infection. Inoculation can be oral, parenteral or any other suitable method. The exact amount of the organism inoculated will vary with well known factors such as the species, size and age of the animal. Determination of the proper quantity of organism to be administered can be determined by one of ordinary skill in the art without undue experimentation. At various times after inoculation, the animals are sacrificed and various organs examined for the presence of the organism. If the organism is not detected, it can be assumed that the gene or sequence disrupted is a virulence determinant.

Confirmation that the sequence identified is a virulence determinant can be obtained by a complementation study. In a complementation study, the wild type sequence is reintroduced into the mutated organism, for example by introduction of an expression vector, and the effect on virulence determined. If the disrupted sequence is associated with virulence, replacement of the sequence should restore virulence. In general, the disrupted gene or sequence is inserted into a suitable expression vector using standard techniques in molecular biology found in standard references and described herein. The expression vector is then introduced into the mutant organism and the virulence of the complemented organism is tested as described above.

The method of the present invention can be used to create strains of mycobacteria which are non-virulent or have reduced virulence. As used herein the term attenuated refers to mutated strains whose virulence is reduced as compared to the same organism in its non-mutated form. Such attenuated mycobacteria can be used in compositions for the treatment and/or prophylaxis of diseases caused by or associated with the organism. This includes compositions designed to stimulate an immune response against a organism, for example, a vaccine. Attenuated strains produced by the method of the present invention are thought to be particularly useful because they make it possible to differentiate between individuals who test positive for the presence of mycobacteria due to vaccination or natural infection based on the presence of the introduced transposon.

Likewise, polypeptides encoded by sequences identified by the method of the present invention as being involved in virulence can be used to stimulate an immune response in an

animal. In this embodiment, the sequence identified as described herein is placed into an expression vector. If desired, the polypeptide sequence identified can be fused or assembled with additional amino acids to form a fusion protein. Such fusion proteins can be used to increase the solubility or antigenicity of the virulence polypeptide. Methods for the production of fusion proteins are well known in the art and can be found in standard molecular biology references. The expression vector is, in turned, introduced into a suitable prokaryotic or eukaryotic host cell and the encoded polypeptide expressed. The resulting polypeptide is then purified using standard biochemical techniques from lysates of the host cells or from culture medium containing the host cells.

The compositions can be administered to any animal which can become infected with a species of mycobacteria. In one embodiment, the animal is a ruminant animal, more preferably a Bovidae and more preferably still a member of the genus *Bos*. When the composition comprises whole mycobacteria, the bacteria can be live or they can be killed by any suitable means such as heating, chemical treatment, or disruption of the bacterial cell. Bacteria can be in a preserved state such as in a lyophilized form which may or may not be reconstituted prior to administration. The compositions can comprise attenuated bacteria alone, virulence polypeptides alone, or a combination of attenuated bacteria and virulence polypeptides.

The compositions of the present invention can be administered by a variety of routes and methods. Suitable routes and methods of administration include orally, parenterally, by inhalation spray, rectally, intradermally, transdermally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques. In one embodiment, the complexes are administered by injection. In another embodiment, the compositions are administered orally. In yet another embodiment, the compositions are administered by inhalation. Methods for the formulation of drugs is well known in the art and is discussed in, for example, Hoover, John E., *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, Pennsylvania (1975), and Liberman, H.A. and Lachman, L., Eds., *Pharmaceutical Dosage Forms*, Marcel Decker, New York, N.Y. (1980).

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to the known art using suitable dispersing or

wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are useful in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, and polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.

Suppositories for rectal administration of the compositions discussed herein can be prepared by mixing the active agent with a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, fatty acids, or polyethylene glycols which are solid at ordinary temperatures, but liquid at the rectal temperature, and which will therefore melt in the rectum and release the composition.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered *per os*, the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration.

The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The amount of attenuated organism and/or virulence determinants that can be combined with the carrier materials to produce a single dosage form will vary depending upon the patient or animal and the particular mode of administration. Compositions of the present invention can be given as a single administration or in multiple administrations over a period of time. If desired, after the initial administration or series of administrations, additional periodic administrations (e.g. boosters) of the composition can be given.

The attenuated organisms and/or virulence determinants can be administered in combination with a pharmaceutically acceptable immune system stimulant or adjuvant. Examples of such immune system stimulants or adjuvants include, but are not limited to, Alum (aluminum phosphate or aluminum hydroxide), Freund's adjuvant, calcium phosphate, beryllium hydroxide, dimethyl dioctadecyl ammonium bromide, saponins, polyanions, e.g. poly A:U, Quil A, inulin, lipopolysaccharide endotoxins, liposomes, lysolecithins, zymosan, propionibacteria, mycobacteria, and cytokines, such as, interleukin-1, interleukin-2, interleukin-4, interleukin-6, interleukin-12, interferon- $\alpha$ , interferon- $\gamma$ , granulocyte-colony stimulating factor.

In another embodiment, the virulence determinants identified by the method of the present invention are used for diagnosis of mycobacterial infection. Biological samples can be obtained from a subject suspected of suffering from a mycobacterial infection. Biological samples include any sample of tissue or fluid isolated from an individual. Examples of biological samples, include, but are not limited to, plasma, serum, spinal fluid, lymph fluid, sections of skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, mucus, milk, blood cells, tumors, tumor cells, and organs. Biological samples also include samples obtained from *in vitro* cell culture, for example, cells grown in culture, including putatively



infected cells and recombinant cells, cell components, and conditioned media resulting from the culture of cells in culture medium..

In one embodiment, diagnosis is made based on the presence of polynucleotide sequences identified by the method of the present invention. In this embodiment, a biological sample which contains nucleic acids is obtained from an individual. Polynucleotides whether in the form of DNA or RNA are obtained from the sample using well established techniques which are known to those in the art and can be found in standard molecular biology references, such as those cited herein. In one embodiment, diagnosis is made based on hybridization of specific polynucleotide probes to sequences encoding virulence determinants identified by the present invention. Probes should be of sufficient length to provide specificity. In general, probes are at least 4 nucleotides in length, more preferably at least 8 nucleotides in length, even more preferably at least 12 nucleotides in length, and more preferably still at least 20 nucleotides in length. Probes used can be obtained from mycobacteria using standard methods, for example, by the use of restriction enzyme digestion to obtain suitable nucleic acid fragments which are then inserted into a cloning vector, which is in turn introduced into a suitable host cell. The host cells are then grown under conditions allowing replication of the cloning vector, and the desired sequences isolated and used as probes. Alternatively, probes can be produced by chemical synthesis in automated systems by any suitable method, for example, the phosphoramidite method of Beaucage and Carruthers (*Teta. Letts.*, 22:1859-1862, 1981). When used for hybridization, it is desirable that the probes be completely complementary to the sequence to be detected, but probes which exhibit only partial complementarity can be used. Hybridization probes can, and often do, contain detection moieties. Such detection moieties include, but are not limited to, radioactive labels, such as radionuclides, fluorophores or fluorochromes, peptides, enzymes, vitamins and steroids.

In order to insure specificity, hybridizations should be conducted under highly stringent conditions. As is recognized in the art, stringency is a combination of many factors such as temperature and the composition of the hybridization and wash solutions. Thus, many different conditions can result in the same degree of stringency. In general, highly stringent conditions are achieved by hybridization in a solution of 6X SSC or SSPE at a temperature 20-25°C below the melting temperature ( $T_m$ ) for DNA-DNA hybrids and 10-15°C below the  $T_m$  for DNA-RNA hybrids followed by washing in 0.1X SSC or SSPE at

42°C. Even higher stringency conditions can be achieved by washing in 0.1X SSC or SSPE at 50-65°C.

In situations where the amount of nucleic acid which can be obtained from the sample is small, it may be desirable to amplify the sequences of interest by methods such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR) (see, Wu and Wallace, *Genomics*, 4:560-569, 1989; Landegren et al., *Science*, 241:1077-1080, 1988), transcription amplification (Kwoh et al., *Proc. Natl. Acad. Sci. USA*, 86:1173-1177, 1989), self-sustained sequence replication (Guatelli et al., *Proc. Natl. Acad. Sci. USA*, 87:1874-1878, 1990), and nucleic acid based sequence amplification (NASBA). In one preferred embodiment, amplification is by PCR. Optimization of conditions for conducting PCR must be determined for each reaction and can be accomplished without undue experimentation by one of ordinary skill in the art. In general, methods for conducting PCR can be found in U.S. Patent Nos 4,965,188, 4,800,159, 4,683,202, and 4,683,195; Ausbel et al., eds., *Short Protocols in Molecular Biology*, 3<sup>rd</sup> ed., Wiley, 1995; and Innis et al., eds., *PCR Protocols*, Academic Press, 1990.

Diagnosis of infection by the presence of sequences identified by the method of the present invention can be achieved by visualization of PCR products of a characteristic size. Individuals testing positive due to natural infection can be differentiated from individuals who have received attenuated vaccine by the presence of the transposon which will result in an increase in the size of the amplification product. Alternatively, the amplification products could be detected by hybridization to specific probes as described above.

In another embodiment, diagnosis is made by detection of polypeptides encoded by the sequences identified by the method of the present invention. In one embodiment, such detection is by an immunological assay. Various immunological assays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in vivo immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, immunoprecipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In

another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled.

Antibodies, either polyclonal or monoclonal, against polypeptides identified by the method of the present invention for use in immunological assays can be produced by known methods. If polyclonal antibodies are desired, an animal is immunized with a virulence polypeptide identified by the method of the present invention. The composition used for immunization can comprise the polypeptide alone or may further comprise an adjuvant or other immune system stimulant. Further, the polypeptide can be conjugated to a carrier molecule or be part of a fusion protein in order to increase antigenicity. Following immunization, serum is collected from the immunized animals and treated according to well established methods. If desired, the antibody can be purified using known techniques such as affinity chromatography. Methods for the production of polyclonal antibodies are well known in the art and can be found for example in Ausubel et al., *Short Protocols in Molecular Biology*, 3rd ed. Wiley, 1995.

Likewise, monoclonal antibodies can be produced using well known techniques. In general, immortal antibody producing cell lines are created by cell fusion, direct transformation of B lymphocytes with oncogenic DNA, or transfection of Epstein-Barr virus. Panels of hybridomas can then be screened for the production of suitable monoclonal antibodies using standard techniques. Methods for the production of monoclonal antibodies are well known in the art and can be found for example in U.S. Patent Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,466,917; 4,472,500; 4,491,632; and 4,493,890.

Also encompassed by the present invention are diagnostic kits. Such kits can contain probes, primers and/or antibodies for the detection of polynucleotides or polypeptides identified by the method of the present invention. The probes, primers and antibodies may, optionally, incorporate a detection moiety such as those described herein. The kits may further comprise buffers, reagents and instructions necessary for the use of the contents of the kits to detect the presence of the polynucleotides and/or polypeptides.

## EXAMPLES

### Example 1

#### Bacterial Strains, Growth Conditions, and Recombinant DNA

A virulent clinical isolate of *M. paratuberculosis* (strain K-10) was used. *M. paratuberculosis* cultures were grown standing at 37°C in a complete growth medium comprising Middlebrook 7H9 broth enriched with oleic acid albumin dextrose complex, 0.4% casamino acids containing vitamins, 40 µg/mL L-tryptophan, 0.5 µg/mL mycobactin J (Allied Monitor, Fayette, MO), and 0.05% Tween 80. *Escherichia coli* DH5α cells, used as cloning hosts were grown on Luria-Bertani (LB) agar or broth supplemented with 50 µg/mL kanamycin. The conditionally replicating (temperature sensitive) recombinant mycobacteriophage phAE94 (Bardarov et al., *Proc. Natl. Acad. Sci. USA*, 94:10961-10966, 1997) used to deliver the transposon Tn5367 (McAdam et al., *Infect. Immun.* 63:1004-1012, 1995) was propagated in *Mycobacterium smegmatis* mc<sup>2</sup>155 at 30°C as has been described previously (Bardarov et al., *Proc. Natl. Acad. Sci. USA*, 94:10961-10966, 1997). The transposon Tn5367 is a derivative of the insertion sequence IS1096 from *M. smegmatis* and carries the *aph* gene conferring kanamycin resistance.

### Example 2

#### Transposon Mutagenesis

*M. paratuberculosis* cultures were grown to approximately  $1.5 \times 10^8$  cfu/mL (OD<sub>600</sub> 0.38-0.75). Cultures (50 mL) were concentrated by centrifugation and resuspension in 1 mL of MP buffer (50 mM Tris-HCL, pH 7.6, 150 mM NaCl, 2 mM CaCl<sub>2</sub>). Bacterial cells and phage were incubated at a non-permissive temperature (37°C) at the ratios and for the times indicted in Table 1. After completion of the adsorption time, 2 mL of prewarmed stop buffer (MP buffer containing 20 mM sodium citrate and 0.2% Tween 20) was added to prevent further phage infections. Kanamycin resistant (kan<sup>r</sup>) colonies were selected on complete growth medium without Tween plus 15 g/L agar containing 50 µg/mL kanamycin at 37°C. In five independent experiments, 5,620 transductants were obtained (Table 1). In further experiments, the number of transductants was increased to 13,526. This provides a representation of approximately 95% of the genome. Probability (%) values for the representation of the mutant pool were calculated using the formula  $\ln(1-P) = N \times \ln(1-$

1/4500) assuming a genome size of 5.0 Mb (allowing a 5% underestimation error for the reported size) and 4500 target genes and where  $N = 13479$  for  $P = 95\%$ .

To verify that transposition events had occurred in these mutants, genomic DNA was isolated using standard techniques (Sambrook et al., *Molecular Cloning*, 2nd ed., Cold Spring Harbor Press, 1989) and digested with *Pst*I which does cleave the transposon. The digests were then hybridized overnight under stringent conditions of 65°C in Rapid-hyb buffer (Amersham-Pharmacia, Piscataway, NJ) using radiolabeled plasmid pYUB285 which carries the transposon as a probe followed by two, 20 minute washes in 2X SSC at 28°C, a 15 minutes wash in 0.5X SSC at 65°C and a final 15 minute wash in 0.1X SSC at 65°C. Each mutant gave, as expected, one hybridizable band with at least four distinct sizes observed (Figure 1). This confirmed that transpositions had occurred and that each transformant represented transpositions at different chromosomal locations. Furthermore, all mutants gave the same pattern of IS900 hybridizable bands as expected for derivatives of strain K-10, and none of the samples hybridized with TM4 DNA indicating that hybridization was not due to the residual presence of vector phage DNA.

### Example 3

#### Subcloning and DNA Sequencing

Chromosomal DNA from transposon mutant GPM207 and pACYC184 vector DNA was digested with *Eco*RI, ligated into the corresponding *Eco*RI site in the pACYC184 vector and transformed into *E. coli* DH5 $\alpha$  cells by using standard methods (Ausubel et al., *Short Protocols in Molecular Biology*, 3rd ed., Wiley, 1995). *E. coli* were cultured as described above and kanamycin resistant transformants isolated. Plasmid DNA was isolated from selected transformants and subjected to automated sequencing using the BigDye Terminator Cycle Sequencing Ready Reaction (Perkin Elmer) and the ABI Prism 310 Genetic Analyzer (Perkin Elmer). Chromosomal DNA sequences at the junctions of the transposon insertions were obtained by cycle sequencing outward from the transposon using the primers 5'-GGTCAGCGCAGGCGAAGCCC (BETH-F, SEQ ID NO: 1) and 5'-GCCAGGTCACACTGCCCCC (BETH-R, SEQ ID NO: 2). The results are shown in Figure 2. An 8 bp duplication was observed at the transposon-chromosomal junction (SEQ ID NOS: 3 & 4) (Figure 2). This duplication was also reported by Pelicic et al. (*Proc. Natl. Acad. Sci. USA*, 94:10955-10960, 1997) for transpositions of this element into five different

genes in *M. bovis* BCG. The nucleotide sequence derived from BETH-F was translated based on the mycobacterial codon usage. A BLAST search identified the chromosomal gene carrying the transposon insertion as homologous to the *M. leprae xerC* gene (GenBank No.Z97369; SEQ ID NO: 6) encoding a putative integrase/recombinase (52% identity and 63% similarity for the region sequenced, see Figure 2).

#### Example 4

##### Susceptibility of Growing and Non-Growing Populations of

##### *M. paratuberculosis* in Broth Culture to Antimicrobial Agents

Antimicrobial agents (antibiotics) tested were the fluoroquinolone Bay y 3118 , and D-cycloserine. The aminoglycoside amikacin, which kills both growing and non-growing *M. paratuberculosis*, was included as a control. *M. paratuberculosis* strain K-10 was grown in complete Middlebrook 7H9 medium containing mycobactin J as described above to an optical density (OD<sub>600</sub>) of 0.3 to 0.4. For non growing conditions, cells (200 ml) were harvested at room temperature, washed in MSS (Middlebrook 7H9 salt solution: 1.0 g/L KH<sub>2</sub>PO<sub>4</sub>, 0.05 g/L MgSO<sub>4</sub>, 0.5 g/L NH<sub>4</sub>SO<sub>4</sub>, 2.5 g/L Na<sub>2</sub>HPO<sub>4</sub>, 0.0005 g/L CaCl<sub>2</sub>, 0.001 g/L ZnSO<sub>4</sub>, and 0.001 g/L CuSO<sub>4</sub>), and resuspended in MSS as a single-cell suspension (Williams et al., *J. Clin. Microbiol.*, 37:304-309, 1999). Aliquots (10 ml at a cell density of  $2 \times 10^8$  CFU/mL) were placed in sterile tissue culture flasks, and antibiotics were added at the following final concentrations Bay y 3118: 0.075 µg/mL (5X MIC) and 0.3 µg/mL (20X MIC); D-cycloserine: 125 µg/mL (5X MIC) and 500 µg/mL (20X MIC); amikacin: 10 µg/mL (5X MIC), and 40 µg/mL (20X MIC). These cultures and a control without antibiotics (0X) were incubated at 37°C and appropriate dilutions were plated in triplicate onto complete Middlebrook 7H9 medium at various time points. When these cells were inoculated into complete Middlebrook medium (growing conditions), they displayed normal growth (growth control). For growing conditions, cells were treated as described except that the growth control (0X) was diluted 1:10 and all cells were washed and resuspended in complete medium instead of MSS. The cells were also inoculated into MSS (no-growth control).

The results are shown in Figure 3 and show that Bay y 3118 at 5X the MIC does not kill non growing bacteria, but has a bactericidal action on growing bacteria. At both 5X and 20X the MIC, D-cycloserine had a moderate bactericidal effect on both growing and non

growing bacteria. Amikcin, as expected, was bactericidal for both growing and non growing bacteria, but bacteria in stasis were particularly more susceptible.

#### Example 5

##### Susceptibility of Growing and Non-Growing Populations of

##### *M. paratuberculosis* in Macrophage Culture to Antimicrobial Agents

Bovine macrophages of the BOMAC line (Stabel and Stabel, *Vet. Immunol. Immunopathol.*, 45:211-220, 1995) are infected with single-cell suspensions of mutated bacteria as described in Example 4 at a MOI of 10:1. Infected BOMAC cells are then incubated at 39°C in RPMI-1640 tissue culture medium containing Bay y 3118 at 5X the MIC for three days. After the incubation period, the infected BOMAC cells are lysed with 0.25% SDS, and the viable bacteria recovered by centrifugation. These bacteria are used to infect a fresh culture of BOMAC cells, and this procedure is repeated until each pool of mutants has been passed 3 times through BOMAC cells. The bacteria recovered from the final passage and sample from earlier passages are then subjected to molecular characterization as described in Example 3.

#### Example 6

##### Virulence Testing of *M. paratuberculosis* in Susceptible Mice

Groups of 6 to 8 week old beige mice were infected orally with non mutated (wild type) *M. paratuberculosis* strain K-10 and euthanized at various times post infection. Bacterial loads in liver, spleen and ileum were determined. Intestinal wall tissue was fixed and stained with hematoxylin and eosin for histological assessment. Mice were given either a high infectious dose of 5 doses of  $1 \times 10^8$  bacteria administered on alternate days (Experiment I) or a low infectious dose of  $1 \times 10^4$  bacteria in a single dose (Experiment II). The results are given in Table 2. With the high infectious dose, the bacteria continued to grow in the spleen during the 8-week period, but bacterial load in the liver leveled off at three weeks. Effective multiplication during the 8-week period was also observed in the terminal ileum with an *in vivo* generation time of about one week. These results showed that *M. paratuberculosis* can infect beige mice through the intestinal mucosa. A higher multiplication in the liver and spleen as compared to the ileum, however, indicated that the mice were experiencing a systemic infection. Thus, using the high infectious dose, beige mice infected with *M.*

*paratuberculosis* did not parallel all the features of ruminant paratuberculosis. Under the conditions of Experiment II, the ileum displayed the greatest bacterial load. Bacterial multiplication continued in all three organs for the 8-week period. Thus, using a lower dose, oral infection of beige mice with *M. paratuberculosis* followed a course similar to the more time consuming monoassociated nude mouse intragastric model (Hamilton et al., *Vet Pathol.* 28:146-155, 1991).

#### Example 7

##### Virulence Tested of Mutated Bacteria in Susceptible Mice

Beige mice are inoculated orally with a single dose of  $1 \times 10^4$  bacteria as described in Example 6. For each mutant tested, there is a test group of mice that receives the mutated organism and a positive control group that receives the non mutated parental (wild type) strain from which the mutated organisms are derived. At various times after inoculation, animals are euthanized and bacterial loads in liver, spleen and ileum are determined as described in Example 6. Mutant strains which do not show continued multiplication in tissues as compared to the corresponding controls are considered to be non-virulent.

#### Example 8

##### Screening of Mutant Bacteria for Ability to Stimulate Immunity

Mutant bacteria which have been found to be non virulent by the method of Example 7 are tested to determine their ability to stimulate immunity against subsequent infection with non-mutated, virulent strains. Beige mice are inoculated orally with mutant, non-virulent strains as described in Example 6. A second group of mice acts as a control group and receives only vehicle. At various times after inoculation, mice are challenged with  $1 \times 10^4$  bacteria of the non-mutated, virulent parental strain. At various times after challenge, mice are euthanized and bacterial loads in liver, spleen and ileum are determined as described in Example 6. Mutated strains which are found to confer immunity are further tested to determine optimal dosage rates and methods of immunization, for example, single or multiple administration, oral versus parenteral administration.



TABLE 1

| Expt. <sup>1</sup> | OD <sub>600</sub><br>culture <sup>2</sup> | Ration<br>Ph/B <sup>3</sup> | Ads<br>Time<br>(hours)<br><sub>4</sub> | Transd.<br>Freq. <sup>5</sup> | Transp<br>Freq <sup>6</sup> | Kan <sup>r</sup><br>mutants <sup>7</sup> | N <sup>8</sup> | P<br>value <sup>9</sup> |
|--------------------|---|-----------------------------|--|-------------------------------|-----------------------------|--|----------------|-------------------------|
| I                  | 0.48                                      | 20                          | 4                                      | 5.4x10 <sup>-8</sup>          | 1.0x10 <sup>-6</sup>        | 1344                                     | 1344           | 26%                     |
| II                 | 0.48                                      | 200                         | 4                                      | 5.1x10 <sup>-9</sup>          | 9.8x10 <sup>-7</sup>        | 1275                                     | 2619           | 42%                     |
| III                | 0.38                                      | 25                          | 6                                      | 7.0x10 <sup>-9</sup>          | 1.8x10 <sup>-7</sup>        | 176                                      | 2795           | 46%                     |
| IV                 | 0.38                                      | 25                          | 24                                     | 5.4x10 <sup>-9</sup>          | 1.4x10 <sup>-7</sup>        | 136                                      | 2931           | 48%                     |
| V                  | 0.75                                      | 350                         | 4                                      | 1.1x10 <sup>-9</sup>          | 3.6x10 <sup>-5</sup>        | 2689                                     | 5620           | 71%                     |

<sup>1</sup> Experiment number<sup>2</sup> OD<sub>600nm</sub> of *M. paratuberculosis* at harvest<sup>3</sup> Ratio of phAE94 PFU at 30°C to the number of *M. paratuberculosis* K-10 CFU<sup>4</sup> Adsorption time in hours at 37°C<sup>5</sup> Transduction frequency: number of kanamycin-resistant colonies obtained at 37°C per infecting phage particle.<sup>6</sup> Transposition frequency: number of kanamycin-resistant colonies obtained at 37°C per recipient cell.<sup>7</sup> Total number of kanamycin-resistance colonies obtained at 37°C (putative transposon mutants)<sup>8</sup> Cumulative number of kanamycin-resistant colonies obtained<sup>9</sup> Probability (%) value for the representation of the mutant pool assuming random transposition.

TABLE 2

| Week | CFU/g (mean of all mice in group $\pm$ SEM) |                           |                           |                           |                           |                           |
|------|---|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|      | Liver                                       |                           | Spleen                    |                           | Ileum                     |                           |
|      | I   | II                        | I                         | II                        | I                         | II                        |
| 1    | $5.9 \pm 0.6 \times 10^7$                   | $7.9 \pm 0.4 \times 10^1$ | $2.7 \pm 0.3 \times 10^7$ | $1.6 \pm 0.3 \times 10^2$ | $3.5 \pm 0.6 \times 10^4$ | $5.9 \pm 0.6 \times 10^3$ |
| 2    | $1.4 \pm 0.8 \times 10^8$                   | $1.5 \pm 0.5 \times 10^1$ | $1.1 \pm 0.4 \times 10^8$ | $1.8 \pm 0.4 \times 10^2$ | $4.0 \pm 0.3 \times 10^4$ | $2.2 \pm 0.2 \times 10^4$ |
| 3    | $2.5 \pm 0.4 \times 10^8$                   | Not done                  | $1.7 \pm 0.5 \times 10^8$ | Not done                  | $9.9 \pm 0.6 \times 10^4$ | Not done                  |
| 4    | Not done                                    | $3.0 \pm 0.2 \times 10^2$ | Not done                  | $1.6 \pm 0.3 \times 10^2$ | Not done                  | $2.5 \pm 0.2 \times 10^4$ |
| 8    | $2.9 \pm 0.6 \times 10^8$                   | $1.1 \pm 0.6 \times 10^3$ | $5.6 \pm 0.4 \times 10^8$ | $5.9 \pm 0.4 \times 10^3$ | $2.2 \pm 0.3 \times 10^5$ | $1.3 \pm 0.3 \times 10^4$ |

### CONCLUSION

In light of the detailed description of the invention and the examples presented above, it can be appreciated that the several aspects of the invention are achieved.

It is to be understood that the present invention has been described in detail by way of illustration and example in order to acquaint others skilled in the art with the invention, its principles, and its practical application. Particular formulations and processes of the present invention are not limited to the descriptions of the specific embodiments presented, but rather the descriptions and examples should be viewed in terms of the claims that follow and their equivalents. While some of the examples and descriptions above include some conclusions about the way the invention may function, the inventors do not intend to be bound by those conclusions and functions, but put them forth only as possible explanations.

It is to be further understood that the specific embodiments of the present invention as set forth are not intended as being exhaustive or limiting of the invention, and that many alternatives, modifications, and variations will be apparent to those of ordinary skill in the art in light of the foregoing examples and detailed description. Accordingly, this invention is intended to embrace all such alternatives, modifications, and variations that fall within the spirit and scope of the following claims.